The Proteasome Inhibitor Velcade Enhances Rather Than Reduces Disease in Mouse Hepatitis Coronavirus-infected Mice

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2010 May 21

PMID 20484516

Citations 20

Authors

Matthijs Raaben

Guy C M Grinwis

Peter J M Rottier

Cornelis A M de Haan

Affiliations

Soon will be listed here.

Abstract

Many viruses, including coronaviruses (CoVs), depend on a functional cellular proteasome for efficient infection in vitro. Hence, the proteasome inhibitor Velcade (bortezomib), a clinically approved anticancer drug, shown in an accompanying study (M. Raaben et al., J. Virol. 84:7869-7879, 2010) to strongly inhibit mouse hepatitis CoV (MHV) infection in cultured cells, seemed an attractive candidate for testing its antiviral properties in vivo. Surprisingly, however, the drug did not reduce replication of the virus in mice. Rather, inhibition of the proteasome caused enhanced infection with lethal outcome, calling for caution when using this type of drug during infection.

Citing Articles

Effects of immunoproteasome inhibition on acute respiratory infection with murine hepatitis virus strain 1.

Steigmann J, Zhou X, Suttenberg L, Salman I, Rehmathullah Z, Weinberg J J Virol. 2024; 98(12):e0123824.

PMID: 39508578 PMC: 11650983. DOI: 10.1128/jvi.01238-24.

Upregulated Proteasome Subunits in COVID-19 Patients: A Link with Hypoxemia, Lymphopenia and Inflammation.

Alfaro E, Diaz-Garcia E, Garcia-Tovar S, Zamarron E, Mangas A, Galera R Biomolecules. 2022; 12(3).

PMID: 35327634 PMC: 8946050. DOI: 10.3390/biom12030442.

SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: beneficial effects of melatonin.

Mehrzadi S, Karimi M, Fatemi A, Reiter R, Hosseinzadeh A Pharmacol Ther. 2021; 224:107825.

PMID: 33662449 PMC: 7919585. DOI: 10.1016/j.pharmthera.2021.107825.

COVID-19 Usurps Host Regulatory Networks.

Curran C, Rivera D, Kopp J Front Pharmacol. 2020; 11:1278.

PMID: 32922297 PMC: 7456869. DOI: 10.3389/fphar.2020.01278.

The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Tundo G, Sbardella D, Santoro A, Coletta A, Oddone F, Grasso G Pharmacol Ther. 2020; 213:107579.

PMID: 32442437 PMC: 7236745. DOI: 10.1016/j.pharmthera.2020.107579.

References

Nencioni A, Schwarzenberg K, Brauer K, Schmidt S, Ballestrero A, Grunebach F . Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood. 2006; 108(2):551-8. DOI: 10.1182/blood-2005-08-3494. View

Teale A, Campbell S, van Buuren N, Magee W, Watmough K, Couturier B . Orthopoxviruses require a functional ubiquitin-proteasome system for productive replication. J Virol. 2008; 83(5):2099-108. PMC: 2643736. DOI: 10.1128/JVI.01753-08. View

La Frazia S, Amici C, Santoro M . Antiviral activity of proteasome inhibitors in herpes simplex virus-1 infection: role of nuclear factor-kappaB. Antivir Ther. 2007; 11(8):995-1004. View

Adams J . Development of the proteasome inhibitor PS-341. Oncologist. 2002; 7(1):9-16. DOI: 10.1634/theoncologist.7-1-9. View

Basler M, Lauer C, Beck U, Groettrup M . The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol. 2009; 183(10):6145-50. DOI: 10.4049/jimmunol.0901596. View

Kane R, Farrell A, Sridhara R, Pazdur R . United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res. 2006; 12(10):2955-60. DOI: 10.1158/1078-0432.CCR-06-0170. View

Oikawa T, Sasaki T, Nakamura M, Shimamura M, Tanahashi N, Omura S . The proteasome is involved in angiogenesis. Biochem Biophys Res Commun. 1998; 246(1):243-8. DOI: 10.1006/bbrc.1998.8604. View

Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik H . Structure of 20S proteasome from yeast at 2.4 A resolution. Nature. 1997; 386(6624):463-71. DOI: 10.1038/386463a0. View

Raaben M, Posthuma C, Verheije M, te Lintelo E, Kikkert M, Drijfhout J . The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle. J Virol. 2010; 84(15):7869-79. PMC: 2897594. DOI: 10.1128/JVI.00485-10. View

10.

Luo H, Zhang J, Cheung C, Suarez A, McManus B, Yang D . Proteasome inhibition reduces coxsackievirus B3 replication in murine cardiomyocytes. Am J Pathol. 2003; 163(2):381-5. PMC: 1868224. DOI: 10.1016/S0002-9440(10)63667-X. View

11.

Schenkein D . Use of proteasome inhibition in the treatment of lung cancer. Clin Lung Cancer. 2005; 6 Suppl 2:S89-96. DOI: 10.3816/clc.2004.s.021. View

12.

Raaben M, Whitley P, Bouwmeester D, Setterquist R, Rottier P, de Haan C . Improved microarray gene expression profiling of virus-infected cells after removal of viral RNA. BMC Genomics. 2008; 9:221. PMC: 2397413. DOI: 10.1186/1471-2164-9-221. View

13.

Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, Tanaka K, Omura S, Kikuchi H . Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun. 1995; 217(3):1070-7. DOI: 10.1006/bbrc.1995.2878. View

14.

King R, Deshaies R, Peters J, Kirschner M . How proteolysis drives the cell cycle. Science. 1996; 274(5293):1652-9. DOI: 10.1126/science.274.5293.1652. View

15.

Satheshkumar P, Anton L, Sanz P, Moss B . Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes. J Virol. 2009; 83(6):2469-79. PMC: 2648259. DOI: 10.1128/JVI.01986-08. View

16.

Maseda D, Meister S, Neubert K, Herrmann M, Voll R . Proteasome inhibition drastically but reversibly impairs murine lymphocyte development. Cell Death Differ. 2008; 15(3):600-12. DOI: 10.1038/sj.cdd.4402297. View

17.

Subklewe M, Sebelin-Wulf K, Beier C, Lietz A, Mathas S, Dorken B . Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum Immunol. 2007; 68(3):147-55. DOI: 10.1016/j.humimm.2006.12.005. View

18.

Pahler J, Ruiz S, Niemer I, Calvert L, Andreeff M, Keating M . Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res. 2003; 9(12):4570-7. View

19.

Chanan-Khan A, Sonneveld P, Schuster M, Stadtmauer E, Facon T, Harousseau J . Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008; 26(29):4784-90. DOI: 10.1200/JCO.2007.14.9641. View

20.

Raaben M, Prins H, Martens A, Rottier P, de Haan C . Non-invasive imaging of mouse hepatitis coronavirus infection reveals determinants of viral replication and spread in vivo. Cell Microbiol. 2009; 11(5):825-41. PMC: 7162388. DOI: 10.1111/j.1462-5822.2009.01298.x. View